Quantcast
Tag archive for ‘Bristol-Myers Squibb’
By The Dispatch On Monday, November 30th, 2015
0 Comments

Bristol-Myers Squibb’s, Empliciti, receives approval for the treatment of multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple More...

By The Dispatch On Monday, November 23rd, 2015
1 Comment

Opdivo receives FDA nod to treat advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. Photo/Madhero88 More...

By The Dispatch On Monday, December 22nd, 2014
0 Comments

Melanoma drug, Opdivo, gets FDA approval

The U.S. Food and Drug Administration today granted accelerated approval to Opdivo (nivolumab), a new treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who More...

By Robert Herriman On Monday, February 24th, 2014
0 Comments

FDA grants Bristol-Myers Squibb ‘Breakthrough Therapy Designation’ for investigational HCV regimen

Bristol-Myers Squibb Company┬átoday announced that the U.S. Food and Drug Administration (FDA) has granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation for More...



DISPATCH BLOGS

Splash Page logo 300x146 Today in History